Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00JED
|
|||
| Former ID |
DIB013295
|
|||
| Drug Name |
AN-2898
|
|||
| Synonyms |
PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
Click to Show/Hide
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [1] | |
| Company |
Anacor Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H9BN2O3
|
|||
| Canonical SMILES |
B1(C2=C(CO1)C=C(C=C2)OC3=CC(=C(C=C3)C#N)C#N)O
|
|||
| InChI |
1S/C15H9BN2O3/c17-7-10-1-2-13(5-11(10)8-18)21-14-3-4-15-12(6-14)9-20-16(15)19/h1-6,19H,9H2
|
|||
| InChIKey |
UBMGTTRDNUKZMT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 906673-33-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| TSH signaling pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01301508) Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis. U.S. National Institutes of Health. | |||
| REF 2 | An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.